RBX2660 superior to placebo in reducing recurrent Clostridioides difficile infection

Khanna et al. “Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial …

source